Monkey Bcl2 Modifying Factor ELISA kit
- Known as:
- Monkey Bcl2 Modifying Factor Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- e09b0573
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Blue gene shanghai
- Gene target:
- Monkey Bcl2 Modifying Factor ELISA kit
Related genes to: Monkey Bcl2 Modifying Factor ELISA kit
- Gene:
- BCL2 NIH gene
- Name:
- BCL2 apoptosis regulator
- Previous symbol:
- -
- Synonyms:
- Bcl-2, PPP1R50
- Chromosome:
- 18q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: Monkey Bcl2 Modifying Factor ELISA kit
Related articles to: Monkey Bcl2 Modifying Factor ELISA kit
- Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that certain of the MMP‑9 western blot data shown in Fig. 5B on p. 501 had already appeared previously in an article written by different authors at different research institutes in the journal , but which has since been retracted, and also that a pair of the data panels in Fig. 2C and D on p. 499 showing the results of immunofluorescence experiments were duplicates of each other. Furthermore, upon performing an independent analysis of the data in this paper, it came to light that Fig. 2C and D contained a series of internally duplicated groupings/repeated patternings of cells within various of the panels that could not be easily attributed to coincidence. Owing to the fact that the contentious data in the above article had already been published prior to its submission to , the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused. [Molecular Medicine Reports 20: 495‑504, 2019; DOI: 10.3892/mmr.2019.10299]. - Source: PubMed
Publication date: 2026/06/05
Liu YongZhang YanHu MingLi Yu-HuCao Xing-Hua - Cytoskeleton-associated protein 2-like (CKAP2L), a microtubule-associated protein that serves as a structural component of the spindle pole and a cell cycle-related protein, acts as an oncogene in several cancers. This study seeks to elucidate the role of CKAP2L in endometrial cancer (EC) and to investigate its underlying mechanisms. - Source: PubMed
Publication date: 2026/05/20
Wei MinBai XuefeiXi LiliYang Yongxiu - Polycyclic aromatic hydrocarbon derivatives, as a class of environmental pollutants, often exhibit higher toxicity than their parent polycyclic aromatic hydrocarbons, posing potential health risks. This study selected the potentially estrogenic derivative 3-hydroxybenz[a]anthracene as the research subject. Using the estrogen receptor-positive breast cancer cell line T47D as a model, the effects of this compound on cell proliferation, migration, invasion, and apoptosis were evaluated through EdU staining, colony formation, scratch healing, Transwell invasion, and apoptosis assays to evaluate its effects on cell proliferation, migration, invasion, and apoptosis. Western blot analysis was employed to detect the expression of relevant signaling proteins. Results indicate that 3-hydroxybenz[a]anthracene promotes T47D cell proliferation by activating the PI3K/AKT signaling pathway, thereby upregulating AKT, p-AKT, and c-Myc protein expression. It enhances cell migration and invasion by downregulating E-Cadherin and MMP9 while simultaneously upregulating Vimentin and MMP2 protein expression. Furthermore, this compound simultaneously upregulates Bax and Bcl-2 expression, ultimately inducing apoptosis in T47D cells. This study confirms that 3-hydroxybenz[a]anthracene exhibits estrogen-like activity and can influence malignant biological behaviors of breast cancer cells by regulating relevant signaling pathways. These findings provide experimental evidence for further evaluating the endocrine-disrupting effects and breast cancer risks associated with such environmental pollutants. - Source: PubMed
Publication date: 2026/05/20
Song WentingKang XiaoLi XueyanYang YuyanWu Xinke - This work developed and evaluated a crocin-coated zinc-sodium alginate-polyethylene glycol (Zn/SAG/PEG/Cr) nanocomposite as a potential therapeutic against bladder cancer using T24 human carcinoma and Vero kidney epithelial cells. Systematic characterization confirmed successful zinc incorporation, a crystalline inorganic phase, and nanoscale particle size with high compositional purity. MTT assay demonstrated that the nanocomposite exerts selective, concentration-dependent cytotoxicity against T24 cells while maintaining biocompatibility with normal Vero cells. Mechanistic analysis revealed that treatment of the nanocomposite significantly enhanced intracellular reactive oxygen species (ROS) generation, disrupted mitochondrial membrane potential, and compromised plasma membrane integrity. Furthermore, the nanocomposite suppressed pro-inflammatory mediators (TNF-α, NF-κB, COX-2, and IL-6) and induced apoptosis, evidenced by elevated Bax, caspase-3, and caspase-9 levels alongside reduced Bcl-2 expression. Crucially, the formulated nanocomposite attenuated the PI3K/Akt/mTOR signaling pathway, a key regulator of bladder cancer progression. Despite these potent anti-oncogenic effects, challenges remain regarding the precise control of crocin release kinetics and the long-term metabolic clearance of the metallic zinc component. Future prospects involve validating these findings in orthotopic animal models to assess systemic toxicity and optimizing the formulation for targeted intravesical delivery to improve clinical translation. - Source: PubMed
Publication date: 2026/06/02
Wang YueshanAn SenshengMin Yongzheng - The human apoptosis regulator Bcl-2 (Bcl-2) protein plays a pivotal role in many blood cancers such as chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma (MM). By inhibiting apoptosis, Bcl-2 contributes to tumor growth and resistance to chemotherapy. Therefore, inhibiting the anti-apoptotic function of Bcl-2 has emerged as a promising approach to enhance therapeutic efficacy in hematologic malignancies. In this study, we used neural network machine learning models, molecular docking, and molecular dynamics simulations to screen a flavonoid library for potent Bcl-2 inhibitors. We computed four types of molecular fingerprints- Morgan, RDKit, AtomPair, and TopologicalTorsion- of compounds used in Bcl-2 bioassays and generated predictive neural network models based on these descriptors. The quantitative structure-activity relationship (QSAR) model developed with Morgan fingerprints demonstrated superior performance, with an R2 value of 0.804. Among 4857 flavonoids, 83 compounds were predicted to be 'Active'. Subsequently, triplicate molecular docking simulations identified several flavonoids with favorable docking scores relative to Venetoclax, the FDA-approved Bcl-2 inhibitor used to treat CLL, AML, and MM. The top ten docking hits were validated using replicated 200-ns molecular dynamics simulations, where the flavonoid Comp-7 exhibited the most stable root-mean-square deviation (RMSD), which converged within the first 20 ns and remained below 0.2 nm throughout the simulation. Analysis of root-mean-square fluctuation (RMSF), radius of gyration, and hydrogen bonding also supported the stability of the interactions between Comp-7 and Bcl-2. Overall, the flavonoid Comp-7 was predicted as a Bcl-2 inhibitor by the neural network QSAR model, showed a favorable docking score, and exhibited stable interactions in molecular dynamics simulations. Our results can be used to develop effective Bcl-2 inhibitors for the treatment of CLL, AML, and MM. - Source: PubMed
Publication date: 2026/06/02
Tondar AbtinBepari Asim KumarReza Hasan MahmudLiñán Laura CalvetHervás-Marín David